215 FIRST STREET, CAMBRIDGE, MA
Settlement Agreement with REGENXBIO and UPenn Regarding Patent Litigations
Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Ex-99.1
Sarepta Therapeutics Approves 2026 Equity Incentive Plan at Annual Meeting
Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Annual Report to Security Holders
Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
CEO Departure - Douglas Ingram to Retire by End of 2026
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Quarterly Holdings Report for Institutional Managers
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
S-8 POS